Savara review

The short version

Savara is built around a single medicine for a single rare lung disease. In autoimmune PAP, the small air sacs in the lungs fill with a thick fluid, because the immune system blocks a signal that cells need to clear it. Patients run short of breath, and the main treatment is a hospital procedure to wash out their lungs. Molbreevi, an inhaled drug, could become the first approved medicine, with an FDA decision due on 22 November 2026.

The latest FDA decision: delayed

On 15 April 2026 Savara said the FDA had moved its decision from 22 August to 22 November, because its answers to FDA questions counted as a major addition to the application (Savara). It was a delay rather than a judgment on the drug, but the shares fell about 7% around the news, as our FDA Decision Calendar shows.

What it makes

Molbreevi is an inhaled form of GM-CSF, the signal that autoimmune PAP blocks. Patients breathe it in once a day through a handheld nebulizer. In the Phase 3 IMPALA-2 trial, with 164 adults, it improved how well the lungs pass oxygen into the blood compared with placebo, and it was published in the New England Journal of Medicine. Long-term data shown in 2026 pointed to continued improvements in lung function and quality of life (Savara Q2 2026 results).

Is it really new?

Yes. Molbreevi would be the first drug approved for this disease. Its active ingredient is a natural signal rather than a new chemical, but delivering it directly to the lungs is what makes it practical.

The competition

The real competitor is the current way of life with the disease. Whole lung lavage requires general anesthesia and a hospital stay. Some doctors use Leukine, a related protein, off-label, without approved evidence for this use. The disease is very rare, about seven people per million (Global Genes), so sales depend on finding patients and on a high price typical of rare disease drugs.

Money

Savara lost $40.2 million in Q2 2026 and held about $173 million of cash and short-term investments on 30 June, plus about $30 million of debt. That is about a year of spending at the current pace, and the launch will cost more. About $150 million of extra funding opens up with an FDA approval. A delay or rejection would make new share sales likely.

Earlier setbacks matter here. In May 2025 the FDA refused to review the first application because of missing manufacturing information (PharmaManufacturing). Savara filed again in December 2025, with Fujifilm as the maker of the active ingredient.

Risks

• All-or-nothing. The company has no second drug in the clinic.
• Manufacturing. Past problems were about production, and switching suppliers always carries risk.
• Small market. Diagnosing patients and convincing doctors to treat them takes time.
• Funding. Share sales could dilute holders, particularly if approval slips.

Our take

Savara is a clean story: a serious disease, no approved drug and a positive Phase 3 trial. The FDA’s three-month delay is a nuisance, not a warning sign in itself. Worth about $1 billion, the company is a straightforward test of whether a very rare disease can support a business. The decisions in the US, the UK and Europe all come within months of each other.